Eisai, Biogen In Co-Development Deal For Two Eisai Alzheimer's Drugs
This article was originally published in PharmAsia News
Executive Summary
Eisai and Biogen Idec have agreed to co-develop and market the Japan drug maker's two drugs for reducing amyloid plaque buildup in the brain, a cause of Alzheimer's disease.